NCT05727267CompletedPhase 1
TherVacB_Phase1a: Open phase 1a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatitis B vaccine candidate in healthy volunteers
Source: EU CTIS (euclinicaltrials.eu) · Last updated 4 Jul 2025
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 30 (actual)
- First submitted
- 7 Oct 2024
- Start date
- 8 Jul 2025
- Lead sponsor
- University Medical Center Hamburg-Eppendorf
- Diseases
- Hepatitis B
- NCT number
- NCT05727267
- EU CT number
- 2024-514231-26-00
- EudraCT number
- 2022-000635-23
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 30
- 2 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study, not your situation.
Sites (2)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Bernhard-Nocht-Institut Fuer Tropenmedizin Coordinator of this site? Confirm its status | Hamburg | Germany | Completed |
| Klinikum der Universitaet Muenchen AöR Coordinator of this site? Confirm its status | Munich | Germany | Completed |
This page is information, not medical advice. Discuss any trial with your doctor.